HEALTH

St. Paul Brands launches two pain relievers

BY Michael Johnsen

GARDEN GROVE, Calif. St. Paul Brands recently announced the introduction of tw effervescent pain-relieving products—AcetaDrink and AsperDrink.

The effervescent analgesics—AcetaDrink contains 500 mg of acetaminophen and AsperDrink 81 mg of aspirin—represent an alternative to the pill-averse consumer looking for moderate pain relief.

The effervescents, which taste like soda according to St. Paul Brands, also ensure faster delivery of the analgesic as compared to tablets.

Suggested retail price for AcetaDrink is $6.99 for a box with three doses. AsperDrink sells for a suggested $6.49.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
HEALTH

GlaxoSmithKline wins recommendation to sell Alli in Europe

BY Michael Johnsen

LONDON GlaxoSmithKline won a recommendation from European regulators Thursday that it be allowed to sell its weight loss drug Alli over-the-counter in Europe.

The European Medicines Agency said it had recommended the switch from prescription-only to nonprescription for a 60-milligram dose of alli, the same dose approved for sale OTC in the United States. The European Commission now needs to rubber-stamp the recommendation.

The European Medicines Agency said it had recommended the switch from prescription-only to nonprescription for a 60-milligram dose of alli, the same dose approved for sale OTC in the United States. The European Commission now needs to rubber-stamp the recommendation.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
HEALTH

FDA endorses industry iniative to update children’s cough-cold product labeling

BY Michael Johnsen

ROCKVILLE, Md The Food and Drug Administration on Wednesday issued a consumer update regarding the use of cough/cold products in children that reinforces the agency’s support of an industry initiative that changes label recommendations on pediatric cough/cold products to no longer recommend use in children under the age of four, and explains the reasoning behind why the agency hasn’t requested an immediate product recall of current labeling.

“The voluntary actions announced by the Consumer Healthcare Products Association are intended to help prevent and reduce the misuse of these products in children and to better inform consumers about their safe and effective use,” the agency stated. “CHPA’s voluntary actions will not affect the availability of the medicines, but will result in a transition period where the instructions for using some OTC cough and cold medicines in children will be different from others. Some product instructions will state ‘do not use’ in children under 4 years of age, while others will instruct not to use in children under 2 years of age. FDA does not typically request that OTC products with previous labeling be removed from the shelves during a voluntary label change such as this one. The agency recommends following the dosage instructions and warnings on the label that accompanies the medication if you have or buy a product that does not have the voluntarily modified labeling.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?